首页 > 最新文献

Advances in Clinical and Experimental Medicine最新文献

英文 中文
Improving sepsis mortality prediction with machine learning: A comparative study of advanced classifiers and performance metrics. 用机器学习改进败血症死亡率预测:高级分类器和性能指标的比较研究。
IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-08-01 DOI: 10.17219/acem/194660
Puyu Zhou, Jiazheng Duan, Jianqing Li

Background: High sepsis mortality rates pose a serious global health problem. Machine learning is a promising technique with the potential to improve mortality prediction for this disease in an accurate and timely manner.

Objectives: This study aimed to develop a model capable of rapidly and accurately predicting sepsis mortality using data that can be quickly obtained in an ambulance, with a focus on practical application during ambulance transport.

Material and methods: Data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) dataset were used to compare the performance of 11 machine learning algorithms against the widely utilized quick Sequential Organ Failure Assessment (qSOFA) score. A dynamic updating model was implemented. Performance was evaluated using area under the curve (AUC) and precision-recall area under the curve (PRAUC) scores, and feature importance was assessed with SHapley Additive exPlanations (SHAP) values.

Results: The light gradient boosting machine (LightGBM) model achieved the highest AUC (0.79) and PRAUC (0.44) scores, outperforming the qSOFA score (AUC = 0.76, PRAUC = 0.40). The LightGBM also achieved the highest PRAUC (0.44), followed by Optuna_LightGBM (0.43) and random forest (0.42). The dynamically updated and tuned model further improved performance metrics (AUC = 0.79, PRAUC = 0.44) compared to the base model (AUC = 0.76, PRAUC = 0.39). Feature importance analysis offers clinicians insights for prioritizing patient assessments and interventions.

Conclusions: The LightGBM-based model demonstrated superior performance in predicting sepsis-related mortality in an ambulance setting. This study underscores the practical applicability of machine learning models, addressing the limitations of previous research, and highlights the importance of real-time updates and hyperparameter tuning in optimizing model performance.

背景:脓毒症的高死亡率是一个严重的全球健康问题。机器学习是一种很有前途的技术,有可能以准确和及时的方式提高对这种疾病的死亡率预测。目的:本研究旨在建立一种能够快速准确预测脓毒症死亡率的模型,利用救护车上可以快速获得的数据,重点关注救护车运输过程中的实际应用。材料和方法:使用重症监护医学信息市场- iv (MIMIC-IV)数据集的数据,将11种机器学习算法的性能与广泛使用的快速顺序器官衰竭评估(qSOFA)评分进行比较。实现了动态更新模型。使用曲线下面积(AUC)和曲线下精确召回面积(PRAUC)评分评估性能,使用SHapley加性解释(SHAP)值评估特征重要性。结果:光梯度增强机(LightGBM)模型获得最高的AUC(0.79)和PRAUC(0.44)评分,优于qSOFA评分(AUC = 0.76, PRAUC = 0.40)。PRAUC最高的是LightGBM(0.44),其次是Optuna_LightGBM(0.43)和random forest(0.42)。与基础模型(AUC = 0.76, PRAUC = 0.39)相比,动态更新和调整的模型进一步提高了性能指标(AUC = 0.79, PRAUC = 0.44)。特征重要性分析为临床医生优先考虑患者评估和干预提供了见解。结论:基于lightgbm的模型在预测败血症相关死亡率方面表现优异。本研究强调了机器学习模型的实际适用性,解决了以往研究的局限性,并强调了实时更新和超参数调优在优化模型性能中的重要性。
{"title":"Improving sepsis mortality prediction with machine learning: A comparative study of advanced classifiers and performance metrics.","authors":"Puyu Zhou, Jiazheng Duan, Jianqing Li","doi":"10.17219/acem/194660","DOIUrl":"10.17219/acem/194660","url":null,"abstract":"<p><strong>Background: </strong>High sepsis mortality rates pose a serious global health problem. Machine learning is a promising technique with the potential to improve mortality prediction for this disease in an accurate and timely manner.</p><p><strong>Objectives: </strong>This study aimed to develop a model capable of rapidly and accurately predicting sepsis mortality using data that can be quickly obtained in an ambulance, with a focus on practical application during ambulance transport.</p><p><strong>Material and methods: </strong>Data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) dataset were used to compare the performance of 11 machine learning algorithms against the widely utilized quick Sequential Organ Failure Assessment (qSOFA) score. A dynamic updating model was implemented. Performance was evaluated using area under the curve (AUC) and precision-recall area under the curve (PRAUC) scores, and feature importance was assessed with SHapley Additive exPlanations (SHAP) values.</p><p><strong>Results: </strong>The light gradient boosting machine (LightGBM) model achieved the highest AUC (0.79) and PRAUC (0.44) scores, outperforming the qSOFA score (AUC = 0.76, PRAUC = 0.40). The LightGBM also achieved the highest PRAUC (0.44), followed by Optuna_LightGBM (0.43) and random forest (0.42). The dynamically updated and tuned model further improved performance metrics (AUC = 0.79, PRAUC = 0.44) compared to the base model (AUC = 0.76, PRAUC = 0.39). Feature importance analysis offers clinicians insights for prioritizing patient assessments and interventions.</p><p><strong>Conclusions: </strong>The LightGBM-based model demonstrated superior performance in predicting sepsis-related mortality in an ambulance setting. This study underscores the practical applicability of machine learning models, addressing the limitations of previous research, and highlights the importance of real-time updates and hyperparameter tuning in optimizing model performance.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1393-1402"},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143389661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Matrix metalloproteinases and tissue inhibitors of metalloproteinases as potential biomarkers for pulmonary arterial hypertension: A review. 基质金属蛋白酶和组织金属蛋白酶抑制剂作为肺动脉高压潜在生物标志物的研究进展
IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-08-01 DOI: 10.17219/acem/204831
Wiktoria U Kozłowska, Jakub Łomzik, Karol Kamiński, Remigiusz Kazimierczyk

Pulmonary arterial hypertension (PAH) is a rare and progressive syndrome that is frequently diagnosed at an advanced stage due to the nonspecific nature of its symptoms. Current research aims to identify novel diagnostic tools, including biomarkers, to facilitate earlier detection and differentiation of pulmonary hypertension (PH) subtypes. Matrix metalloproteinases (MMPs) play a critical role in the pathogenesis of PAH through extracellular matrix (ECM) remodeling, with their activity tightly regulated by tissue inhibitors of metalloproteinases (TIMPs). This review summarizes existing studies on the potential of MMPs and TIMPs as biomarkers for PAH. Our analysis highlights significant differences in MMP concentrations between PAH patients and healthy controls. In particular, MMP-2, MMP-7 and MMP-9 exhibit promising prognostic value, which could contribute to risk stratification and support clinical decision-making in the future. However, large-scale, randomized prospective studies involving well-characterized patient cohorts are necessary to confirm their clinical utility and clarify their mechanistic roles in PAH pathogenesis.

肺动脉高压(PAH)是一种罕见的进行性综合征,由于其症状的非特异性,通常在晚期诊断。目前的研究旨在确定新的诊断工具,包括生物标志物,以促进早期检测和区分肺动脉高压(PH)亚型。基质金属蛋白酶(Matrix metalloproteinases, MMPs)通过细胞外基质(extracellular Matrix, ECM)重塑在PAH的发病机制中发挥关键作用,其活性受到组织金属蛋白酶抑制剂(tissue inhibitors of metalloproteinases, TIMPs)的严格调控。本文综述了MMPs和TIMPs作为多环芳烃生物标志物潜力的现有研究。我们的分析强调了PAH患者和健康对照之间MMP浓度的显著差异。特别是,MMP-2、MMP-7和MMP-9表现出良好的预后价值,有助于未来的风险分层和支持临床决策。然而,有必要进行大规模、随机、前瞻性的研究,包括特征明确的患者队列,以证实它们的临床应用,并阐明它们在PAH发病机制中的作用。
{"title":"Matrix metalloproteinases and tissue inhibitors of metalloproteinases as potential biomarkers for pulmonary arterial hypertension: A review.","authors":"Wiktoria U Kozłowska, Jakub Łomzik, Karol Kamiński, Remigiusz Kazimierczyk","doi":"10.17219/acem/204831","DOIUrl":"https://doi.org/10.17219/acem/204831","url":null,"abstract":"<p><p>Pulmonary arterial hypertension (PAH) is a rare and progressive syndrome that is frequently diagnosed at an advanced stage due to the nonspecific nature of its symptoms. Current research aims to identify novel diagnostic tools, including biomarkers, to facilitate earlier detection and differentiation of pulmonary hypertension (PH) subtypes. Matrix metalloproteinases (MMPs) play a critical role in the pathogenesis of PAH through extracellular matrix (ECM) remodeling, with their activity tightly regulated by tissue inhibitors of metalloproteinases (TIMPs). This review summarizes existing studies on the potential of MMPs and TIMPs as biomarkers for PAH. Our analysis highlights significant differences in MMP concentrations between PAH patients and healthy controls. In particular, MMP-2, MMP-7 and MMP-9 exhibit promising prognostic value, which could contribute to risk stratification and support clinical decision-making in the future. However, large-scale, randomized prospective studies involving well-characterized patient cohorts are necessary to confirm their clinical utility and clarify their mechanistic roles in PAH pathogenesis.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immunogenic mutanome of breast cancer: Advances, challenges and future directions in neoantigen-based immunotherapy. 乳腺癌的免疫原性突变:新抗原免疫治疗的进展、挑战和未来方向。
IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-08-01 DOI: 10.17219/acem/205014
Almohanad A Alkayyal, Nizar H Saeedi, Mamdouh S Moawadh

Breast cancer (BC) remains a leading cause of cancer-related mortality worldwide, underscoring the need for novel, more effective therapies. Neoantigen-based immunotherapy - which harnesses tumor-specific somatic mutations to boost immune recognition - has emerged as a particularly promising strategy. Advances in next-generation sequencing and computational immunopeptidomics now allow systematic mapping of the tumor mutanome and rapid identification of immunogenic neoantigens, enabling personalized vaccine design and more precise deployment of immune-checkpoint blockade. However, intratumor heterogeneity, immune-escape mechanisms and the often-limited intrinsic immunogenicity of individual neoepitopes continue to constrain clinical efficacy. This review synthesizes the current landscape of neoantigen-targeted immunotherapies in BC, outlines the principal obstacles to their broader impact and highlights emerging solutions - including improved epitope-prediction algorithms, multi-epitope vaccine constructs and synergistic combination regimens. A deeper understanding of the immunogenic mutanome is expected to translate into more durable and widely applicable treatments for patients with breast cancer.

乳腺癌(BC)仍然是全球癌症相关死亡的主要原因,强调需要新的,更有效的治疗方法。基于新抗原的免疫疗法——利用肿瘤特异性体细胞突变来增强免疫识别——已经成为一种特别有前途的策略。新一代测序和计算免疫肽组学的进步现在允许系统地绘制肿瘤突变组和快速鉴定免疫原性新抗原,从而实现个性化疫苗设计和更精确地部署免疫检查点阻断。然而,肿瘤内异质性、免疫逃逸机制和个体新表位通常有限的内在免疫原性继续制约着临床疗效。本综述综合了BC中新抗原靶向免疫疗法的现状,概述了其广泛影响的主要障碍,并重点介绍了新兴的解决方案,包括改进的表位预测算法、多表位疫苗构建和协同联合方案。对免疫原性突变体的深入了解有望转化为更持久和广泛适用于乳腺癌患者的治疗方法。
{"title":"Immunogenic mutanome of breast cancer: Advances, challenges and future directions in neoantigen-based immunotherapy.","authors":"Almohanad A Alkayyal, Nizar H Saeedi, Mamdouh S Moawadh","doi":"10.17219/acem/205014","DOIUrl":"10.17219/acem/205014","url":null,"abstract":"<p><p>Breast cancer (BC) remains a leading cause of cancer-related mortality worldwide, underscoring the need for novel, more effective therapies. Neoantigen-based immunotherapy - which harnesses tumor-specific somatic mutations to boost immune recognition - has emerged as a particularly promising strategy. Advances in next-generation sequencing and computational immunopeptidomics now allow systematic mapping of the tumor mutanome and rapid identification of immunogenic neoantigens, enabling personalized vaccine design and more precise deployment of immune-checkpoint blockade. However, intratumor heterogeneity, immune-escape mechanisms and the often-limited intrinsic immunogenicity of individual neoepitopes continue to constrain clinical efficacy. This review synthesizes the current landscape of neoantigen-targeted immunotherapies in BC, outlines the principal obstacles to their broader impact and highlights emerging solutions - including improved epitope-prediction algorithms, multi-epitope vaccine constructs and synergistic combination regimens. A deeper understanding of the immunogenic mutanome is expected to translate into more durable and widely applicable treatments for patients with breast cancer.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Eupatorin modulates BCPAP in thyroid cancer cell proliferation via suppressing the NF-κB/P13K/AKT signaling pathways. Eupatorin通过抑制NF-κB/P13K/AKT信号通路调节BCPAP在甲状腺癌细胞增殖中的作用。
IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-08-01 DOI: 10.17219/acem/191595
Weiqi Song, Rongyue Yao, Annamalai Vijayalakshmi, Yuan An

Background: Thyroid carcinoma (TC), the most prevalent endocrine cancer worldwide, has become progressively more common, especially in women. Most TCs are epithelial-derived differentiated TCs, specifically papillary thyroid cancer (PTC). Although there are many therapeutic drugs available, curing TC is a difficult task.

Objectives: A flavone called eupatorin (EUP) obtained from herbs can prevent the growth of many types of cancerous cells. Nonetheless, the mechanisms of EUP's actions against PTC are still unknown.

Material and methods: The goal of our work was to evaluate the mechanisms of EUP (20 and 30 μM/mL) and examine its antiproliferative and apoptotic effects on human PTC cells BCPAP. The MTT test; dual acridine orange/ethidium bromide (AO/EB), rhodamine-123 (Rh-123), and 4',6-diamidino-2-phenylindole (DAPI) staining; adherence assays; and western blot analyses were used to evaluate the antiproliferative and apoptotic properties of EUP on BCPAP cells.

Results: Our research showed that the quantity-dependent administration of EUP inhibited the proliferation of BCPAP cells, which in turn caused apoptosis through the increase in caspase-9 and p53 protein expression and the reduction of proliferating cell nuclear antigen (PCNA) levels. Additionally, when P13K/AKT signaling is inhibited by nuclear factor kappa B (NF-κB), EUP reduces inflammation and BCPAP proliferation.

Conclusions: By blocking the NF-κB and P13K/AKT pathways, EUP can reduce the growth of BCPAP cells and promote cell death.

背景:甲状腺癌(TC)是世界范围内最常见的内分泌肿瘤,已经变得越来越常见,尤其是在女性中。大多数甲状腺癌是上皮来源的分化性甲状腺癌,特别是乳头状甲状腺癌(PTC)。虽然有许多治疗药物可用,但治疗TC是一项艰巨的任务。目的:从草本植物中提取的一种名为eupatorin (EUP)的黄酮可以阻止多种类型癌细胞的生长。尽管如此,EUP对PTC的作用机制仍不清楚。材料与方法:研究20 μM/mL和30 μM/mL的EUP对人PTC细胞BCPAP的抗增殖和凋亡作用。MTT测试;双吖啶橙/溴化乙啶(AO/EB)、罗丹明-123 (Rh-123)和4′,6-二氨基-2-苯基吲哚(DAPI)染色;依从性分析;western blot检测EUP对BCPAP细胞的抗增殖和凋亡作用。结果:我们的研究表明,EUP的剂量依赖抑制了BCPAP细胞的增殖,进而通过增加caspase-9和p53蛋白表达,降低增殖细胞核抗原(PCNA)水平导致细胞凋亡。此外,当P13K/AKT信号被核因子κB (NF-κB)抑制时,EUP可减少炎症和BCPAP增殖。结论:EUP通过阻断NF-κB和P13K/AKT通路,抑制BCPAP细胞生长,促进细胞死亡。
{"title":"Eupatorin modulates BCPAP in thyroid cancer cell proliferation via suppressing the NF-κB/P13K/AKT signaling pathways.","authors":"Weiqi Song, Rongyue Yao, Annamalai Vijayalakshmi, Yuan An","doi":"10.17219/acem/191595","DOIUrl":"10.17219/acem/191595","url":null,"abstract":"<p><strong>Background: </strong>Thyroid carcinoma (TC), the most prevalent endocrine cancer worldwide, has become progressively more common, especially in women. Most TCs are epithelial-derived differentiated TCs, specifically papillary thyroid cancer (PTC). Although there are many therapeutic drugs available, curing TC is a difficult task.</p><p><strong>Objectives: </strong>A flavone called eupatorin (EUP) obtained from herbs can prevent the growth of many types of cancerous cells. Nonetheless, the mechanisms of EUP's actions against PTC are still unknown.</p><p><strong>Material and methods: </strong>The goal of our work was to evaluate the mechanisms of EUP (20 and 30 μM/mL) and examine its antiproliferative and apoptotic effects on human PTC cells BCPAP. The MTT test; dual acridine orange/ethidium bromide (AO/EB), rhodamine-123 (Rh-123), and 4',6-diamidino-2-phenylindole (DAPI) staining; adherence assays; and western blot analyses were used to evaluate the antiproliferative and apoptotic properties of EUP on BCPAP cells.</p><p><strong>Results: </strong>Our research showed that the quantity-dependent administration of EUP inhibited the proliferation of BCPAP cells, which in turn caused apoptosis through the increase in caspase-9 and p53 protein expression and the reduction of proliferating cell nuclear antigen (PCNA) levels. Additionally, when P13K/AKT signaling is inhibited by nuclear factor kappa B (NF-κB), EUP reduces inflammation and BCPAP proliferation.</p><p><strong>Conclusions: </strong>By blocking the NF-κB and P13K/AKT pathways, EUP can reduce the growth of BCPAP cells and promote cell death.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1365-1374"},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142919059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and radiological assessment of the Polish modification of the Ilizarov external fixator for the treatment of intra-articular calcaneal fractures. 用于治疗关节内小关节骨折的波兰改良伊利扎罗夫外固定器的临床和放射学评估。
IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-08-01 DOI: 10.17219/acem/192772
Piotr Morasiewicz, Marcin Pelc, Łukasz Tomczyk, Joanna Kochanska-Bieri, Andrzej Bobiński, Daniele Pili, Paweł Reichert

Background: There is currently no established gold standard for the treatment of calcaneal fractures.

Objectives: To conduct a clinical and radiological evaluation of patients following intra-articular calcaneal fractures treated with the Polish modification of the Ilizarov method.

Material and methods: This was a 2-center retrospective study. We evaluated 27 patients (2 women and 25 men) aged 28-73 years (mean age 50.5 years) after treatment of intra-articular calcaneal fractures with the Polish modification of the Ilizarov method. We assessed pain using a visual analogue scale (VAS), American Orthopedic Foot and Ankle Society (AOFAS) scores, patient satisfaction with treatment, use of analgesics, duration of Ilizarov treatment, length of hospital stay, duration of surgery, patient's declared willingness to choose the same treatment again, complications, degenerative changes, Böhler angle, inflection angle, and Gissane angle.

Results: The mean follow-up period was 3 years and 2 months. Following treatment, the mean VAS pain score was 2.3. Prior to surgery, all patients were taking analgesics in comparison with only 2 patients (7.4%) at long-term follow-up. The treatment was rated as satisfactory by 11 patients, with 16 patients rating it as highly satisfactory. The mean post-treatment AOFAS score was 76.6 points. The Ilizarov fixator was removed after a mean period of 88 days. The mean duration of hospital stay was 7.4 days. The mean duration of the procedure was 44 min. All patients would choose the same treatment again. Complications were observed in 5 patients. The long-term follow-up visit revealed degenerative changes in the talocalcaneal joint in 8 patients. The median Böhler angle was 5.5° preoperatively and 28.5° postoperatively, p < 0.001. The median preoperative inflection angle of 160° decreased to 145°, p < 0.001. The median preoperative Gissane's angle of 119° increased significantly to a median postoperative value of 143°, p < 0.001.

Conclusions: The patients achieved good clinical and radiological outcomes.

背景目前尚无治疗小关节骨折的金标准:对采用波兰改良伊利扎洛夫法治疗关节内小关节骨折的患者进行临床和放射学评估:这是一项由两个中心进行的回顾性研究。我们对27名患者(2名女性和25名男性)进行了评估,他们的年龄在28-73岁之间(平均年龄为50.5岁),均接受过波兰改良伊利扎洛夫法治疗关节内小关节骨折。我们使用视觉模拟量表(VAS)、美国骨科足踝协会(AOFAS)评分、患者对治疗的满意度、止痛药的使用、Ilizarov治疗持续时间、住院时间、手术持续时间、患者再次选择相同治疗方法的意愿、并发症、退行性改变、Böhler角、拐角和Gissane角进行了评估:平均随访时间为 3 年零 2 个月。治疗后,平均 VAS 疼痛评分为 2.3。手术前,所有患者都服用止痛药,而在长期随访中,只有两名患者(7.4%)服用止痛药。11名患者对治疗效果表示满意,16名患者对治疗效果表示非常满意。治疗后的平均 AOFAS 评分为 76.6 分。伊利扎洛夫固定器平均在 88 天后移除。平均住院时间为 7.4 天。手术的平均时间为 44 分钟。所有患者都会再次选择相同的治疗方法。5名患者出现并发症。长期随访显示,8 名患者的距趾关节出现退行性病变。中位伯勒角术前为5.5°,术后为28.5°,P < 0.001。术前的中位拐角为 160°,术后降至 145°,P < 0.001。术前 Gissane's 角的中位数为 119°,术后中位数增至 143°,p < 0.001:患者取得了良好的临床和放射学效果。
{"title":"Clinical and radiological assessment of the Polish modification of the Ilizarov external fixator for the treatment of intra-articular calcaneal fractures.","authors":"Piotr Morasiewicz, Marcin Pelc, Łukasz Tomczyk, Joanna Kochanska-Bieri, Andrzej Bobiński, Daniele Pili, Paweł Reichert","doi":"10.17219/acem/192772","DOIUrl":"10.17219/acem/192772","url":null,"abstract":"<p><strong>Background: </strong>There is currently no established gold standard for the treatment of calcaneal fractures.</p><p><strong>Objectives: </strong>To conduct a clinical and radiological evaluation of patients following intra-articular calcaneal fractures treated with the Polish modification of the Ilizarov method.</p><p><strong>Material and methods: </strong>This was a 2-center retrospective study. We evaluated 27 patients (2 women and 25 men) aged 28-73 years (mean age 50.5 years) after treatment of intra-articular calcaneal fractures with the Polish modification of the Ilizarov method. We assessed pain using a visual analogue scale (VAS), American Orthopedic Foot and Ankle Society (AOFAS) scores, patient satisfaction with treatment, use of analgesics, duration of Ilizarov treatment, length of hospital stay, duration of surgery, patient's declared willingness to choose the same treatment again, complications, degenerative changes, Böhler angle, inflection angle, and Gissane angle.</p><p><strong>Results: </strong>The mean follow-up period was 3 years and 2 months. Following treatment, the mean VAS pain score was 2.3. Prior to surgery, all patients were taking analgesics in comparison with only 2 patients (7.4%) at long-term follow-up. The treatment was rated as satisfactory by 11 patients, with 16 patients rating it as highly satisfactory. The mean post-treatment AOFAS score was 76.6 points. The Ilizarov fixator was removed after a mean period of 88 days. The mean duration of hospital stay was 7.4 days. The mean duration of the procedure was 44 min. All patients would choose the same treatment again. Complications were observed in 5 patients. The long-term follow-up visit revealed degenerative changes in the talocalcaneal joint in 8 patients. The median Böhler angle was 5.5° preoperatively and 28.5° postoperatively, p < 0.001. The median preoperative inflection angle of 160° decreased to 145°, p < 0.001. The median preoperative Gissane's angle of 119° increased significantly to a median postoperative value of 143°, p < 0.001.</p><p><strong>Conclusions: </strong>The patients achieved good clinical and radiological outcomes.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1321-1329"},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142455709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety assessment of turmeric-boswellia-sesame formulation in healthy adult volunteers: An open-label prospective study. 姜黄-乳香草-芝麻配方在健康成人志愿者中的安全性评估:一项开放标签前瞻性研究。
IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-08-01 DOI: 10.17219/acem/193023
Se-Kwon Kim, Venkatesan Jayachandran, Thanh Sang Vo, Isuru Wijesekara

Background: Turmeric and boswellia supplements have gained popularity for their anti-inflammatory and antioxidant properties. It is important to critically assess the safety of such supplements for prolonged use.

Objectives: To assess the safety and tolerability of turmeric-boswellia-sesame oil formulation (TBSF) in healthy human volunteers.

Material and methods: Forty participants were supplemented with TBSF at a dose of 2,000 mg daily for 90 days. Safety assessments were performed at baseline, as well as on day 30, 60 and 90. Adverse events were monitored throughout the study period. Any evidence of hepatotoxicity injury or drug induced liver injury (DILI) was assessed using R value (R ratio/R factor), which is a relative pattern of liver enzymes. Additionally, Hy's law criteria, based on liver enzymes and bilirubin levels, were employed, along with an evaluation of drug-induced serious hepatotoxicity (eDISH) plot. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were calculated, as these values are relevant to the safety of the intervention.

Results: The study found that TBSF supplementation did not cause any adverse effects or clinically significant variations in vital signs, hematological parameters, lipid profile, liver function enzymes, and renal function markers, and all were within the normal range after 90 days of TBSF supplementation. Platelet-to-lymphocyte ratio and NLR did not change significantly and were within the normal range. All the participants when plotted were in the normal range quadrant of the eDISH plot throughout the study period. No abnormal findings were observed in R value and Hy's law criteria, indicating that TBSF does not induce any hepatotoxicity. The present study showed a normal estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), creatinine (Cr), Cr clearance, and BUN/Cr ratio throughout the study period. There was no significant change between these values at 4 abovementioned time points.

Conclusions: The study findings suggest that TBSF is a safe supplement for regular and long-term consumption.

背景:姜黄和乳香草补充剂因其抗炎和抗氧化特性而广受欢迎。重要的是要严格评估这些补充剂长期使用的安全性。目的:评价姜黄乳香香油配方(TBSF)在健康人体的安全性和耐受性。材料和方法:40名参与者以每天2,000 mg的剂量补充TBSF,持续90天。在基线以及第30、60和90天进行安全性评估。在整个研究期间监测不良事件。肝毒性损伤或药物性肝损伤(DILI)的证据采用R值(R比值/R因子)评估,R值是肝酶的相对模式。此外,采用基于肝酶和胆红素水平的Hy定律标准,以及药物引起的严重肝毒性(eDISH)图的评估。计算中性粒细胞与淋巴细胞比率(NLR)和血小板与淋巴细胞比率(PLR),因为这些值与干预的安全性有关。结果:本研究发现,补充TBSF未引起任何不良反应,生命体征、血液学参数、血脂、肝功能酶和肾功能指标均未发生临床显著变化,补充TBSF 90天后均在正常范围内。血小板/淋巴细胞比值及NLR无明显变化,均在正常范围内。在整个研究期间,所有参与者在绘制时都处于eDISH图的正态范围象限。R值和Hy定律标准未见异常,说明TBSF未引起肝毒性。本研究显示,在整个研究期间,肾小球滤过率(eGFR)、血尿素氮(BUN)、肌酐(Cr)、Cr清除率和BUN/Cr比值均正常。在上述4个时间点上,这些值之间没有显著变化。结论:研究结果表明,TBSF是一种安全的补充剂,可以定期和长期食用。
{"title":"Safety assessment of turmeric-boswellia-sesame formulation in healthy adult volunteers: An open-label prospective study.","authors":"Se-Kwon Kim, Venkatesan Jayachandran, Thanh Sang Vo, Isuru Wijesekara","doi":"10.17219/acem/193023","DOIUrl":"10.17219/acem/193023","url":null,"abstract":"<p><strong>Background: </strong>Turmeric and boswellia supplements have gained popularity for their anti-inflammatory and antioxidant properties. It is important to critically assess the safety of such supplements for prolonged use.</p><p><strong>Objectives: </strong>To assess the safety and tolerability of turmeric-boswellia-sesame oil formulation (TBSF) in healthy human volunteers.</p><p><strong>Material and methods: </strong>Forty participants were supplemented with TBSF at a dose of 2,000 mg daily for 90 days. Safety assessments were performed at baseline, as well as on day 30, 60 and 90. Adverse events were monitored throughout the study period. Any evidence of hepatotoxicity injury or drug induced liver injury (DILI) was assessed using R value (R ratio/R factor), which is a relative pattern of liver enzymes. Additionally, Hy's law criteria, based on liver enzymes and bilirubin levels, were employed, along with an evaluation of drug-induced serious hepatotoxicity (eDISH) plot. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were calculated, as these values are relevant to the safety of the intervention.</p><p><strong>Results: </strong>The study found that TBSF supplementation did not cause any adverse effects or clinically significant variations in vital signs, hematological parameters, lipid profile, liver function enzymes, and renal function markers, and all were within the normal range after 90 days of TBSF supplementation. Platelet-to-lymphocyte ratio and NLR did not change significantly and were within the normal range. All the participants when plotted were in the normal range quadrant of the eDISH plot throughout the study period. No abnormal findings were observed in R value and Hy's law criteria, indicating that TBSF does not induce any hepatotoxicity. The present study showed a normal estimated glomerular filtration rate (eGFR), blood urea nitrogen (BUN), creatinine (Cr), Cr clearance, and BUN/Cr ratio throughout the study period. There was no significant change between these values at 4 abovementioned time points.</p><p><strong>Conclusions: </strong>The study findings suggest that TBSF is a safe supplement for regular and long-term consumption.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1277-1288"},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142942463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical analysis of 338 cases of dacryolithiasis. 泪石症338例临床分析。
IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-08-01 DOI: 10.17219/acem/192223
Ting Zhang, Wei Zhuo, Wei-Na Wang, Lu Zhao

Background: Dacryolithiasis can occur anywhere in the lacrimal drainage system and is frequently associated with microbial infections. The presence of dacryolithiasis is difficult to determine based on its clinical manifestations, which complicates clinical treatment.

Objectives: To analyze the clinical diagnosis, treatment and characteristics of dacryolithiasis, as well as surgical methods used to treat it and treatment effects over the past 5 years.

Material and methods: A retrospective analysis was performed on the clinical data of 338 patients who were diagnosed with dacryolithiasis at our hospital from January 2017 to December 2021. Patients diagnosed with canaliculitis were treated with canaliculotomy. Dacryocystitis complicated by canaliculitis was treated with endoscopic dacryocystorhinostomy (En-DCR) combined with canaliculotomy. Dacryocystitis accompanied by dacryoliths was treated with En-DCR. Nasolacrimal duct stones were treated with lacrimal intubation. All patients were followed up for 6-12 months.

Results: All patients underwent successful surgery. Of 302 cases (89.35%) with canaliculitis, 297 (98.34%) were cured with canaliculotomy; 5 cases (1.66%) recurred within 1 year after surgery and were cured with canaliculotomy again. Four cases (1.18%) of dacryocystitis complicated by canaliculitis were treated with En-DCR combined with canaliculotomy. In addition, 30 patients (8.88%) had dacryolithiasis; 28 (93.33%) of them were cured, and 2 (6.67%) with common canalicular atresia were cured after lacrimal intubation. Furthermore, 2 patients (0.59%) with nasolacrimal duct stones underwent lacrimal intubation. In addition, 62 cases (20.53%) with canaliculitis tested positive for bacteria, and the top 2 common bacteria were Staphylococcus epidermidis and Streptococcus mitis.

Conclusions: Secretions are the main clinical characteristic of patients with dacryolithiasis, and surgery is the primary treatment method. In addition, different surgical methods correspond to different locations of stones.

背景:泪石症可发生在泪道引流系统的任何部位,并常伴有微生物感染。泪石症的存在很难根据其临床表现来确定,这使临床治疗复杂化。目的:分析近5年来泪石症的临床诊断、治疗、特点、手术方法及治疗效果。材料与方法:回顾性分析我院2017年1月至2021年12月诊断为泪石症的338例患者的临床资料。诊断为小管炎的患者行小管切开术治疗。采用内镜下泪囊鼻腔造口术联合小管切开术治疗泪囊炎合并小管炎。泪囊炎伴泪石用En-DCR治疗。采用泪管插管治疗鼻泪管结石。所有患者随访6 ~ 12个月。结果:所有患者均手术成功。302例小管炎患者(89.35%)行小管切开术治愈297例(98.34%);术后1年内复发5例(1.66%),再次行小管切开术治愈。采用En-DCR联合小管切开术治疗泪囊炎合并小管炎4例(1.18%)。此外,30例(8.88%)患者有泪石症;其中治愈28例(93.33%),经泪道插管后治愈2例(6.67%)。2例(0.59%)鼻泪管结石患者行泪道插管。此外,62例(20.53%)小管炎患者细菌检出阳性,常见细菌前2位为表皮葡萄球菌和密陀球菌。结论:分泌物是泪石症的主要临床特征,手术是治疗泪石症的主要方法。此外,不同的手术方法对应不同的结石位置。
{"title":"Clinical analysis of 338 cases of dacryolithiasis.","authors":"Ting Zhang, Wei Zhuo, Wei-Na Wang, Lu Zhao","doi":"10.17219/acem/192223","DOIUrl":"10.17219/acem/192223","url":null,"abstract":"<p><strong>Background: </strong>Dacryolithiasis can occur anywhere in the lacrimal drainage system and is frequently associated with microbial infections. The presence of dacryolithiasis is difficult to determine based on its clinical manifestations, which complicates clinical treatment.</p><p><strong>Objectives: </strong>To analyze the clinical diagnosis, treatment and characteristics of dacryolithiasis, as well as surgical methods used to treat it and treatment effects over the past 5 years.</p><p><strong>Material and methods: </strong>A retrospective analysis was performed on the clinical data of 338 patients who were diagnosed with dacryolithiasis at our hospital from January 2017 to December 2021. Patients diagnosed with canaliculitis were treated with canaliculotomy. Dacryocystitis complicated by canaliculitis was treated with endoscopic dacryocystorhinostomy (En-DCR) combined with canaliculotomy. Dacryocystitis accompanied by dacryoliths was treated with En-DCR. Nasolacrimal duct stones were treated with lacrimal intubation. All patients were followed up for 6-12 months.</p><p><strong>Results: </strong>All patients underwent successful surgery. Of 302 cases (89.35%) with canaliculitis, 297 (98.34%) were cured with canaliculotomy; 5 cases (1.66%) recurred within 1 year after surgery and were cured with canaliculotomy again. Four cases (1.18%) of dacryocystitis complicated by canaliculitis were treated with En-DCR combined with canaliculotomy. In addition, 30 patients (8.88%) had dacryolithiasis; 28 (93.33%) of them were cured, and 2 (6.67%) with common canalicular atresia were cured after lacrimal intubation. Furthermore, 2 patients (0.59%) with nasolacrimal duct stones underwent lacrimal intubation. In addition, 62 cases (20.53%) with canaliculitis tested positive for bacteria, and the top 2 common bacteria were Staphylococcus epidermidis and Streptococcus mitis.</p><p><strong>Conclusions: </strong>Secretions are the main clinical characteristic of patients with dacryolithiasis, and surgery is the primary treatment method. In addition, different surgical methods correspond to different locations of stones.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1299-1305"},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comorbidity-related risk factors for acute respiratory distress syndrome in sepsis patients: A systematic review and meta-analysis. 脓毒症患者急性呼吸窘迫综合征的合并症相关危险因素:系统回顾和荟萃分析
IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-08-01 DOI: 10.17219/acem/191594
Xin Lin, Yang Liu, Li Kong, Tejin Ba, Bagenna Bao, Shuanglin Zhang, Weihong Liu

Background: Acute respiratory distress syndrome (ARDS) presents a significant challenge in the management of sepsis, with various comorbidities potentially influencing its development. Understanding the impact of these comorbidities is crucial for improving patient outcomes.

Objectives: This meta-analysis was conducted to investigate the relationship between various comorbidities and the development of ARDS in patients with sepsis, with the aim of improving understanding and management of this condition.

Material and methods: The study included adult sepsis patients from 8 studies, totaling 16,964 participants. Risk of bias was assessed using the Newcastle-Ottawa scale (NOS), and the data analysis was performed and reported as pooled odds ratios (ORs) computed using a random-effects model. Heterogeneity and publication bias were assessed using the I2 statistic and Doi plots with the Luis Furuya-Kanamori (LFK) index, respectively.

Results: Chronic obstructive pulmonary disease was significantly associated with an increased risk of ARDS (OR: 1.43, 95% confidence interval (95% CI): 1.02-2.01). Other comorbidities showed no significant associations: diabetes mellitus (DM) (OR: 0.88, 95% CI: 0.69-1.11), hypertension (HTN) (OR: 0.86, 95% CI: 0.56 to 1.34), coronary artery disease (CAD) (OR: 0.95, 95% CI: 0.86-1.06), congestive heart failure (CHF) (OR: 1.08, 95% CI: 0.61 to 1.90), chronic kidney disease (CKD) (OR: 0.89, 95% CI: 0.65-1.22), chronic liver disease (CLD) (OR: 1.13, 95% CI: 0.61-2.09), and cancer (OR: 0.90, 95% CI: 0.59-1.35). Additional analyses indicated moderate-to-high heterogeneity and some evidence of publication bias.

Conclusion: Chronic obstructive pulmonary disease is a notable risk factor for ARDS in sepsis patients, suggesting the need for enhanced surveillance and management in this group. Further research is necessary to understand the mechanisms and explore other potential ARDS risk factors in sepsis.

背景:急性呼吸窘迫综合征(ARDS)在脓毒症的治疗中提出了重大挑战,各种合并症可能影响其发展。了解这些合并症的影响对改善患者预后至关重要。目的:本荟萃分析旨在探讨脓毒症患者各种合并症与ARDS发展之间的关系,以提高对该疾病的认识和管理。材料和方法:本研究纳入8项研究的成人脓毒症患者,共16,964名参与者。使用纽卡斯尔-渥太华量表(NOS)评估偏倚风险,并使用随机效应模型计算合并优势比(ORs)进行数据分析和报告。异质性和发表偏倚分别采用I2统计量和Doi图与Luis Furuya-Kanamori (LFK)指数进行评估。结果:慢性阻塞性肺疾病与ARDS风险增加显著相关(OR: 1.43, 95%可信区间(95% CI): 1.02-2.01)。其他合共病:糖尿病(DM) (OR: 0.88, 95% CI: 0.69-1.11)、高血压(HTN) (OR: 0.86, 95% CI: 0.56 - 1.34)、冠状动脉疾病(CAD) (OR: 0.95, 95% CI: 0.86-1.06)、充血性心力衰竭(CHF) (OR: 1.08, 95% CI: 0.61- 1.90)、慢性肾脏疾病(CKD) (OR: 0.89, 95% CI: 0.65-1.22)、慢性肝病(CLD) (OR: 1.13, 95% CI: 0.61-2.09)和癌症(OR: 0.90, 95% CI: 0.59-1.35)。另外的分析显示了中度到高度的异质性和一些发表偏倚的证据。结论:慢性阻塞性肺疾病是脓毒症患者发生ARDS的重要危险因素,需要加强对该组患者的监测和管理。脓毒症的发生机制和其他潜在的ARDS危险因素有待进一步研究。
{"title":"Comorbidity-related risk factors for acute respiratory distress syndrome in sepsis patients: A systematic review and meta-analysis.","authors":"Xin Lin, Yang Liu, Li Kong, Tejin Ba, Bagenna Bao, Shuanglin Zhang, Weihong Liu","doi":"10.17219/acem/191594","DOIUrl":"10.17219/acem/191594","url":null,"abstract":"<p><strong>Background: </strong>Acute respiratory distress syndrome (ARDS) presents a significant challenge in the management of sepsis, with various comorbidities potentially influencing its development. Understanding the impact of these comorbidities is crucial for improving patient outcomes.</p><p><strong>Objectives: </strong>This meta-analysis was conducted to investigate the relationship between various comorbidities and the development of ARDS in patients with sepsis, with the aim of improving understanding and management of this condition.</p><p><strong>Material and methods: </strong>The study included adult sepsis patients from 8 studies, totaling 16,964 participants. Risk of bias was assessed using the Newcastle-Ottawa scale (NOS), and the data analysis was performed and reported as pooled odds ratios (ORs) computed using a random-effects model. Heterogeneity and publication bias were assessed using the I2 statistic and Doi plots with the Luis Furuya-Kanamori (LFK) index, respectively.</p><p><strong>Results: </strong>Chronic obstructive pulmonary disease was significantly associated with an increased risk of ARDS (OR: 1.43, 95% confidence interval (95% CI): 1.02-2.01). Other comorbidities showed no significant associations: diabetes mellitus (DM) (OR: 0.88, 95% CI: 0.69-1.11), hypertension (HTN) (OR: 0.86, 95% CI: 0.56 to 1.34), coronary artery disease (CAD) (OR: 0.95, 95% CI: 0.86-1.06), congestive heart failure (CHF) (OR: 1.08, 95% CI: 0.61 to 1.90), chronic kidney disease (CKD) (OR: 0.89, 95% CI: 0.65-1.22), chronic liver disease (CLD) (OR: 1.13, 95% CI: 0.61-2.09), and cancer (OR: 0.90, 95% CI: 0.59-1.35). Additional analyses indicated moderate-to-high heterogeneity and some evidence of publication bias.</p><p><strong>Conclusion: </strong>Chronic obstructive pulmonary disease is a notable risk factor for ARDS in sepsis patients, suggesting the need for enhanced surveillance and management in this group. Further research is necessary to understand the mechanisms and explore other potential ARDS risk factors in sepsis.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1255-1265"},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143603364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Keratin biomaterials for wound healing and tissue regeneration: A promising approach in biomedical applications. 角蛋白生物材料用于伤口愈合和组织再生:一种有前途的生物医学应用方法。
IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-08-01 DOI: 10.17219/acem/205998
Marek Konop

Keratin biomaterials, derived from natural sources, offer a promising, biocompatible solution for wound healing and tissue regeneration, though further clinical studies are needed to confirm their efficacy.

天然来源的角蛋白生物材料为伤口愈合和组织再生提供了一种有前景的、生物相容性的解决方案,尽管需要进一步的临床研究来证实其有效性。
{"title":"Keratin biomaterials for wound healing and tissue regeneration: A promising approach in biomedical applications.","authors":"Marek Konop","doi":"10.17219/acem/205998","DOIUrl":"10.17219/acem/205998","url":null,"abstract":"<p><p>Keratin biomaterials, derived from natural sources, offer a promising, biocompatible solution for wound healing and tissue regeneration, though further clinical studies are needed to confirm their efficacy.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1241-1248"},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Caregivers' perspectives on long-term cognitive, psychiatric, psychological, and social outcomes in NMDAR encephalitis: Initial findings from the multi-center prospective SAPIENCE study. 护理者对NMDAR脑炎长期认知、精神、心理和社会结局的看法:来自多中心前瞻性SAPIENCE研究的初步发现
IF 1.9 4区 医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Pub Date : 2025-08-01 DOI: 10.17219/acem/207434
Marta Duda-Sikuła, Ole Jonas Boeken, Víctor Patricio, Chloe Buttard, Marie Benaiteau, Alvaro Mendes, Jerome Honnorat, Ava Easton, Josep Dalmau, Carsten Finke, Donata Kurpas

The SAPIENCE study explores the long-term psychological, social, and systemic challenges faced by caregivers of individuals with NMDAR encephalitis. It aims to inform patientand caregiver-centered strategies that support recovery and wellbeing.

SAPIENCE研究探讨了NMDAR脑炎患者护理人员面临的长期心理、社会和系统挑战。它旨在告知以患者和护理人员为中心的支持康复和福祉的战略。
{"title":"Caregivers' perspectives on long-term cognitive, psychiatric, psychological, and social outcomes in NMDAR encephalitis: Initial findings from the multi-center prospective SAPIENCE study.","authors":"Marta Duda-Sikuła, Ole Jonas Boeken, Víctor Patricio, Chloe Buttard, Marie Benaiteau, Alvaro Mendes, Jerome Honnorat, Ava Easton, Josep Dalmau, Carsten Finke, Donata Kurpas","doi":"10.17219/acem/207434","DOIUrl":"10.17219/acem/207434","url":null,"abstract":"<p><p>The SAPIENCE study explores the long-term psychological, social, and systemic challenges faced by caregivers of individuals with NMDAR encephalitis. It aims to inform patientand caregiver-centered strategies that support recovery and wellbeing.</p>","PeriodicalId":7306,"journal":{"name":"Advances in Clinical and Experimental Medicine","volume":" ","pages":"1249-1253"},"PeriodicalIF":1.9,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144764294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Advances in Clinical and Experimental Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1